Use of miRNAs in Growth Hormone Deficiency (GHD)

NCT06455956 | Recruiting

• 1 other identifier: 821/2022/OSS/UNIPR
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.

Conditions

Growth Hormone Deficiency

Keywords

growth hormone; miRNA; growth hormone deficiency; growth hormone treatment; small for gestational age; Turner syndrome; Noonan syndrome; SHOX deficiency

Outcome Measures

Primary Outcomes (4)

• Assessing new biomarkers for the diagnosis of GHD

  The 1st objective will consist in the enrolment of 200 subjects, nationwide, undergoing standard routine work-up for the diagnosis of GHD. The specific miRNAs will be measured at the time of both stimulation tests in order to include subjects with both confirmed and unconfirmed GHD and guarantee reproducibility; in addition, subjects with organic GH deficiency will be included.

  3 years

• Measuring miRNA changes after 3 months on GH therapy

  The 2nd objective will consist in measuring these specific miRNAs before and at 3 months on treatment in 200 subjects with isolated idiopathic GHD(IIGHD), and in 60 short statured patients born SGA, in 60 having Noonan and Turner syndromes, and in 30 with SHOX deficiency, according to current indications to verify whether changes are confirmed in pubertal versus prepubertal subjects and in conditions other than IIGHD.

  3 years

• Multiple linear regression models

  The 3rd objective will consist in investigating the major determinants of height variations between 0 and 6 months, 0 and 12 months and the variance of growth rate variation between 0 and 6 months including the levels and/or changes in the specific miRNAs at baseline and at 3 months on treatment by using multiple linear regression models to establish early prediction models of growth response..

  3 years

• Measuring miRNA changes between daily and long-acting GH therapy

  The 4th objective will consist in measuring these specific miRNAs before and at 3 months on treatment in children with IIGHD being treated with daily versus longacting GH. Findings will be compared with those in the IIGHD group receiving daily GH treatment as an exploratory task, thus, only a small number of subjects will be enrolled, and anyway as many as possible.

  3 years

Secondary Outcomes (1)

• Sex-specific miRNA changes after 3 months on long-acting GH therapy

  3 years

Eligibility Criteria

• Age: 2 Years - 15 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

All patients will be investigated in routine practice during the normal workup for short stature and stunted growth. Treatment will be also delivered accordind to standard care indications and as established by regulatory agencies in Italy.

You may qualify if:

• Children with short stature and suspicion of GHD
• Subjects with organic GH deficiency

You may not qualify if:

• Subjects with underlying genetic conditions and chronic diseases
• patients having confirmed GHD enrolled for aim 1
• patients with growth failure and born SGA (\>4 yr of age)
• patients with Noonan and Turner syndrome and growth failure
• patients with short stature homeobox-containing gene deficiency (SHOXD) and growth failure
• \- Isolated idiopathic prepubertal naive GHD subjects on long-acting versus daily GH therapy

Sponsors & Collaborators

• University of Parma: lead
• Azienda Ospedaliera Universitaria Policlinico "G. Martino": collaborator
• Ospedali Riuniti Ancona: collaborator
• Federico II University: collaborator
• Azienda Unita Sanitaria Locale di Piacenza: collaborator
• Azienda Ospedaliero Universitaria Policlinico Modena: collaborator
• Azienda USL Reggio Emilia - IRCCS: collaborator
• Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari: collaborator
• Ospedali Riuniti di Foggia: collaborator
• IRCCS Ospedale San Raffaele: collaborator
• Università degli Studi del Piemonte Orientale Amedeo Avogadro: collaborator
• IRCCS Azienda Ospedaliero-Universitaria di Bologna: collaborator
• Istituto Auxologico Italiano: collaborator
• OSPEDALE CARLO POMA ASST MANTOVA: collaborator
• University of Campania Luigi Vanvitelli: collaborator
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: collaborator

Study Sites (1)

University of Parma

Parma, Emilia-Romagna, 43121, Italy

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

Dwarfism, Pituitary; Turner Syndrome; Noonan Syndrome

Condition Hierarchy (Ancestors)

Dwarfism; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases; Bone Diseases, Endocrine; Hypopituitarism; Pituitary Diseases; Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases; Gonadal Dysgenesis; Disorders of Sex Development; Urogenital Abnormalities; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Sex Chromosome Disorders of Sex Development; Male Urogenital Diseases; Heart Defects, Congenital; Cardiovascular Abnormalities; Cardiovascular Diseases; Heart Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Sex Chromosome Disorders; Chromosome Disorders; Genetic Diseases, Inborn; Gonadal Disorders; Craniofacial Abnormalities; Musculoskeletal Abnormalities; Connective Tissue Diseases; Skin and Connective Tissue Diseases

Study Officials

• Maria E Street, MD, PhD

  University of Parma

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Maria E Street, MD, PhD

CONTACT

+39 0521 033557; mariaelisabeth.street@unipr.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 6, 2024
• First Posted: June 13, 2024
• Study Start: April 13, 2023
• Primary Completion: March 31, 2025
• Study Completion: March 1, 2026
• Last Updated: June 13, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)